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Abstract
Background: The optimal duration of firstline chemotherapy in metastatic esophagogastric cancer is unknown. In
most clinical trials therapy was given until tumour progression or limiting toxicity. Maintenance concepts aiming to
prolong the duration of response and maintain quality of life have been established in other tumour types but not in
esophagogastric cancer. S-1 is an oral fluoropyrimidine with proven efficacy in metastatic esophagogastric cancer.
Methods: The Maintenance Teysuno® (S-1) in esophagogastric cancer (MATEO) trial is a multinational, randomized
phase II study that explores the role of S-1 maintenance therapy in Her-2 negative, advanced esophagogastric
adenocarcinoma. After a 12-week firstline platinum-fluoropyrimidine-based chemotherapy patients without tumour
progression are randomized in a 2:1 allocation to receive S-1 alone or continue with the same regimen as during
the primary period. The primary endpoint is overall survival. Secondary endpoints include safety and toxicity,
progression-free survival and quality of life.
Correlative biomarker analyses focus on the identification of a subgroup of patients with a prolonged benefit from
S-1 based maintenance therapy.
Discussion: MATEO will be the first trial to define the role of a S-1 based maintenance therapy in patients having
received a platinum-based firstline chemotherapy.
Trial registration: NCT02128243 (date of registration: 29–04-2014).
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Background
Gastric cancer is the third most common cause of can-
cer related death worldwide. Every year around 725,000
people die due to gastric cancer [1]. A large geographical
variability of the prevalence in Asia, Europe and America
but also within the continents is observed.
In the beginning of the twentieth century most gastric
cancers were located in the distal parts of the stomach.
While during the last decades the overall incidence of
gastric cancer has declined, especially in Western
countries, a strong increase in tumours located at the
esophagogastric junction (adenocarcinoma of the
esophagogastric junction, AEG) occurred [2, 3].
Due to a lack of early symptoms and no effective
screening programs most gastric cancers and AEGs are
diagnosed in irresectable advanced or metastatic stages
in Western countries where even in localized stages long
term survival is below 50% [4, 5]. Relapse rates after sur-
gical treatment with or without perioperative treatment
remain high and a majority of patients will eventually
die due to recurrent or metastatic disease.
In patients with metastatic disease, palliative chemo-
therapy remains the mainstay of treatment. This therapy
aims to prolong survival and to improve or maintain
quality of life by ameliorating tumour-related symptoms.
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Superiority in terms of overall survival compared with
best supportive care was shown in a meta-analysis
published by Wagner and colleagues [6]. Combination
chemotherapy showed significant better outcomes in
comparison with monotherapy.
Until now only Her-2 overexpressing tumours, a sub-
group of ~16% of esophagogastric cancers, are eligible
for biologically targeted therapy in the firstline treatment
of advanced disease. The combination of trastuzumab
with cisplatin and a fluoropyrimidine has shown super-
iority in the phase III Trastuzumab for Gastric Cancer
(ToGa) trial [7]. Following progression to firstline, the
anti-VEGFR2 (vascular endothelial growth factor recep-
tor 2) monoclonal antibody ramucirumab has proven
efficacy either as monotherapy or in combination with
paclitaxel [8, 9].
For patients with Her-2 negative gastric cancers
undergoing firstline treatment for metastatic disease no
approved targeted agents are available, thus chemother-
apy remains the treatment of choice.
Platinum compounds combined with fluoropyrimi-
dines are the mainstay of polychemotherapy for Her-2
negative esophagogastric cancer having shown superior-
ity over older regimens containing methotrexate and
etoposide [10, 11].
For several years the ECF regimen, consisting of epiru-
bicin, cisplatin and 5-FU (5-fluorouracil), has been con-
sidered to be a reference regimen in the metastatic
setting. The REAL2 phase III trial has shown non-
inferiority of oxaliplatin in comparison with cisplatin
and capecitabine in comparison with 5-FU. In addition,
overall survival was modestly longer in the EOX
group (epirubicin, oxaliplatin, capecitabine) compared
with the ECF group. Therefore, EOX is nowadays
considered a standard regimen for metastatic esopha-
gogastric cancer [12].
Adding a taxane to cisplatin and 5-FU (DCF regi-
men) significantly improved the response rate, time-
to-tumour-progression (TTP) and overall survival
(OS) in the TAX 325 trial [13]. Although the grade
3–4 toxicity in terms of diarrhoea, neutropenia and
febrile neutropenia was significantly higher, assess-
ment of quality of life has shown a prolonged time to
definitive worsening of the performance status in the
investigational arm [14]. Due to the increased toxicity
associated with the DCF regimen, several study
groups have performed phase II trials assessing modi-
fications of dosing and scheduling. As a result, modi-
fied DCF [15], FLOT [16], the Gastro-Tax regimen
[17] and others are now being used in daily practice,
although they have not been validated in randomized
phase III trials.
The optimal duration of firstline chemotherapy in
advanced esophagogastric cancer is unknown. In
most phase III trials chemotherapy was given until
tumour progression or the occurrence of inaccepta-
ble toxicity [18].
As an exception, in the REAL2 trial, chemotherapy
was given for a maximum of 8 cycles, each with duration
of 21 days [12]. In the FLAGS trial (cisplatin combined
with S-1 or 5-FU) combination chemotherapy was given
for a maximum of 6 four-weekly cycles (24 weeks),
followed by fluoropyrimidine monotherapy [19].
Dose reductions of chemotherapeutical components
due to toxicity are not uncommon in patients receiving
two- or three-drug combinations. For example, dose re-
ductions were necessary in 35–42% of all patients in the
REAL2 trial [12].
So far no randomized trials have been performed to
determine the optimal duration of firstline chemother-
apy in metastatic esophagogastric cancer. In clinical rou-
tine, firstline chemotherapy is mostly given until tumour
progression or inacceptable toxicity occurs.
Prolonged periods of chemotherapy in responding
patients often lead to increased cumulative toxicity.
Therefore, concepts of therapy de-escalation and the
idea of a maintenance therapy have been addressed in
several tumour entities.
The goal of a maintenance therapy is to consolidate
the tumour regression that has been achieved during the
first months of combination chemotherapy (primary
period) and at the same time to avoid excessive toxicity
which often occurs with prolonged polychemotherapy.
Maintenance concepts have been established in lung
cancer and in colorectal cancer [20, 21].
In this trial S-1 was chosen for assessing the role of
maintenance therapy in advanced esophagogastric can-
cer. S-1 is an oral fluoropyrimidine consisting of tegafur
(a prodrug that is converted to fluorouracil, mainly in
liver microsomes but also in tumour tissue), gimeracil
(an inhibitor of dihydropyrimidine dehydrogenase, which
degrades 5-FU), and oteracil (which inhibits the phos-
phorylation of 5-FU in the gastrointestinal tract, thereby
reducing the toxic effects of 5-FU in the intestinum).
S-1 administered in combination with cisplatin has
been recently approved in Europe for the treatment of
advanced gastric cancer based on the results of the
S1301/FLAGS study [19]. In this study, non-inferiority
of cisplatin/S-1 in comparison with cisplatin/5-FU in
terms of overall survival was shown. Cisplatin/S-1 dis-
played significantly fewer and less severe toxicity than
cisplatin/5-FU.
Objectives
The primary objective of the MATEO trial is to assess
the relative efficacy of S-1 maintenance therapy vs. con-
tinuation of polychemotherapy after a primary phase in
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patients with metastatic esophagogastric cancer in terms
of overall survival.
Secondary objectives include the comparison of S-1
maintenance therapy vs. continuation of polychemother-
apy after primary therapy with respect to safety/toxicity,
progression-free survival and quality of life. Transla-
tional analyses focus on identifying a molecularly defined
subgroup of patients with a sustained benefit from S-1
based maintenance therapy.
Methods/design
The MATEO trial is an open-label, multi-centre,
controlled randomized, parallel-group phase II non-
inferiority trial in patients with metastatic esophagogas-
tric cancer. A randomized control group was incorpo-
rated into the design since reliance on historic data
alone for assessing the relative efficacy of de-escalation
with S-1 and continuation of polychemotherapy is not
appropriate. 297 patients in six European countries are
planned to be randomized.
Trial population
Patients with metastatic, Her-2 negative esophagogastric
adenocarcinoma will be registered before or after the ini-
tiation of a firstline chemotherapy regimen. Patients who
have previously been treated with curative surgery with
or without perioperative (neoadjuvant and/or adjuvant
treatment) are eligible if primary treatment for meta-
static disease starts at least 6 months after the end of
perioperative treatment. Details of the in- and exclusion
criteria can be found in Table 1.
Intervention
All patients start with a firstline treatment period of
12 weeks during which a polychemotherapy regimen can
be chosen by the local investigator, the following regi-
mens being eligible: cisplatin/capecitabine, cisplatin/5-
FU, cisplatin/S-1, FLO/modified Folfox-6, EOX/EOF or
FLOT (Table 2). In week 12 a radiological assessment of
response will be performed. Patients without tumour
progression, with an ECOG-Score of 0 or 1 and without
limiting toxicity are randomized in a 2:1 allocation to
arm A or B (Fig. 1). Randomization will be stratified by
response to primary therapy at time of randomization
(CR or PR vs. SD or non-CR/non-PD (in case of non-
measurable lesions only)), by the applied polychemother-
apy (two-drug vs. three-drug combinations) and by
enrollment before vs. after the primary chemotherapy.
Patients in arm A receive S-1 monotherapy with a
dosage of 30 mg/m2 given twice daily per os for 14 days
followed by a seven-day rest.
Patients in arm B will continue polychemotherapy
with the same regimen as used during the primary
phase.
In case of toxicity, chemotherapy doses are reduced
according to protocol specifications. Furthermore, in
Arm B single agents of the combination regimens can be
stopped (e.g. stop of platinum- or taxane-compounds in
case of polyneuropathy).
Treatment in the maintenance period will be continued
until tumour progression or limiting toxicity.
Quality of life
Quality of life (QoL) is assessed using the EORTC QLQ-
C30 and STO22 questionnaires [22–24]. Baseline QoL
will be measured within 14 days before starting the first
cycle of firstline treatment. The evaluation will be
repeated at the end of primary therapy. During the
maintenance therapy and follow-up QoL assessment will
be performed at week 4, 9, 13, 18 and 27 after the end of
the primary period (including patients who do not con-
tinue with maintenance therapy due to tumour progres-
sion or toxicity).
Nutritional assessment
The nutritional state will be evaluated using the Nutri-
tional Risk Screening (NRS) 2002 [25]. Evaluation will be
performed before primary chemotherapy, at the end of
the primary period, every 9 weeks during maintenance
therapy and at the end-of-treatment (EOT).
Correlative biomarker analyses
The translational part of this trial aims to identify
subgroups of patients with a sustained, beneficial re-
sponse during S-1 maintenance therapy. Blood samples
are taken at different time points during the study, poly-
morphisms of genes related to the fluoropyrimidine me-
tabolism as well as microRNA profiles and cytokine
profiles will be measured to identify predictive markers
for S-1 maintenance therapy. Formalin-fixed paraffin-
embedded tumour tissue will be used for molecular
analyses, to correlate clinical efficacy with recently
published molecular defined subtypes.
Statistical considerations
The statistical goal of this randomized phase II trial is to
formally assess whether de-escalation with S-1 is not
substantially inferior to continuation of polychemother-
apy in terms of overall survival. If S-1 can be demon-
strated to be non-inferior based on the pre-specified
non-inferiority margin and the selected significance
level, de-escalation with S-1 can be considered to be
promising for further evaluation and subsequent phase
III studies, taking into consideration additional potential
benefits like decreased toxicity, cost or ease of applica-
tion. Statistically, the goal is to test whether the ratio of
the hazard of death with S-1 divided by the hazard of
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Signed written informed consent incl. participation in
translational research
2. Male or female patient 18 years or older
3. Histologically confirmed metastatic or locally advanced
unresectable gastric adenocarcinoma or adenocarcinoma of
the esophagus or the esophagogastric junction (Her-2/neu
negative or with unknown Her-2/neu status)
4. Adjuvant/neoadjuvant or perioperative chemotherapy or
(chemo-)radiotherapy must have been finished at least
6 months before start of the induction therapy
5. For patients enrolled before induction therapy: No previous
systemic treatment (i.e. chemotherapy) for metastatic disease
6. For patients enrolled after induction therapy: Having finished
a three-months induction therapy (6 cycles of a bi-weekly
regimen, 4 cycles of a three-weekly regimen or 3 cycles of a
four-weekly regimen) without tumour progression or limiting
toxicity
7. ECOG Performance Score 0–1 (Karnofsky Performance status
> = 80%)
8. Ability for oral intake of the study drug, patients with tumour-
related problems with oral intake might be registered if the
symptom is expected to be improved during induction ther-
apy (e.g. due to a tumour stenosis)
9. Female patient of childbearing potential (i.e. did not undergo
surgical sterilization – hysterectomy, bilateral tubal ligation, or
bilateral oophorectomy - and is not post-menopausal for at
least 24 consecutive months) with a negative pregnancy test
10. Hematology and biochemistry laboratory results within the
limits normally expected for the patient population, defined
by the following:
• Absolute neutrophil count ≥1500/μl
• Platelet count ≥100,000/μl
• Leukocyte count >3000/μl
• Hemoglobin ≥9 g/dL or 5.59 mmol/l, previous
transfusions (>3 days) of erythrocytes are allowed
• Total bilirubin ≤1.5 times the upper limit of normal
(ULN), in patients with known Meulengracht syndrom
≤3 x ULN
• AST ≤ 3xULN in absence of liver metastases, or
≤5xULN in presence of liver metastases
• ALT ≤3xULN in absence of liver metastases, or
≤5xULN in presence of liver metastases
• Creatinine clearance ≥30 mL/min according to
Cockcroft-Gault formula
1. Previous major sugery within the last 28 days before the start of
the induction treatment. The implantation of a central venous
access (e.g. porth-a cath system) or a diagnostic laparoscopy are
allowed.
2. History of other malignant tumours within the last 5 years
before start of induction treatment, except basal cell carcinoma
or curatively excised cervical carcinoma in situ
3. Known brain metastases
4. Concurrent radiotherapy involving target lesions used for this
study. Concurrent palliative radiation for non-target lesions is
allowed if other target lesions are available outside the involved
field; previous radiotherapy including target lesions must
have been finished at least 28 days before start of induction
treatment.
5. For patients enrolled before the induction therapy: Previous
systemic treatment (i.e. chemotherapy) for metastatic disease
6. Known active HBV, HCV infection or documented HIV infection
7. Serious concomitant disease or medical condition that by
judgment of the Investigator renders the patient at high risk of
treatment complications
8. Clinically relevant coronary artery disease (NYHA functional
angina classification III/IV), congestive heart failure (NYHA III/IV),
clinically relevant cardiomyopathy, history of myocardial
infarction in the last 3 months or high risk of uncontrolled
arrhythmia
9. Female patient pregnant or breast feeding
10. Female patient of childbearing potential (i.e. did not undergo
surgical sterilization – hysterectomy, bilateral tubal ligation, or
bilateral oophorectomy - and is not post-menopausal for at
least 24 consecutive months) not willing to use an adequate
method of contraception to avoid pregnancy throughout the
study and for up to 26 weeks after the end of treatment.
Male patient not willing to use an adequate method of
contraception to avoid conception throughout the study and
for up to 26 weeks after the end of treatment in such a
manner that the risk of pregnancy is minimized.
11. Concurrent treatment with other experimental drugs or
participation in another clinical trial with any investigational
drug within 60 days prior to start of induction (e.g. one of the
allowed standard chemotherapies (see above) with or without
additional placebo within a clinical trial is allowed)
12. Chronic diarrhea or short bowel syndrome
13. Known hypersensitivity to S-1, other fluoropyrimidines or
platinum compounds. Contraindication to receive S-1 or the
polychemotherapy (induction & arm B) chosen for this patient
as per current Summary of Product Characteristics. Known DPD
deficiency
14. For patients enrolled before the induction therapy: Grade ≥ 2
peripheral neuropathy
15. Known drug abuse/alcohol abuse
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death with continued polychemotherapy is less than the
pre-specified non-inferiority margin.
Selection of a non-inferiority margin is based upon a
combination of clinical judgement and statistical reason-
ing. Literature data suggests that continuation of
polychemotherapy will lead to a median overall survival
of roughly 8 months (calculated from the time of
randomization in week 12) [12, 13, 18]. With this me-
dian survival, discussions with clinical experts revealed,
the largest increase of the risk of death with S-1 that
one is willing to accept for this phase II trial is 33%, if –
in addition – safety seems to be in favor of S-1 leading
to a non-inferiority margin on the hazard ratio scale of
1.33. The significance level for testing non-inferiority
was set to one-sided α = 10%. These choices of both the
non-inferiority margin and the significance level can be
considered as an initial gatekeeper reflecting the ultim-
ate goal of a phase II design to allow for unbiased evalu-
ation of treatment differences and to support further
decision making within the community and to decide
whether a phase III trial is justified.
Furthermore, a power of 80% under the alternative hy-
pothesis that both treatment arms are in fact associated
with the same underlying hazard rates, i.e. HR = 1
(translating into median overall survival of 8 months in
both treatment arms) was pre-specified.
Table 2 Chemotherapeutical regimens for use during the primary period
Two drug combinations: Three drug combinations:
Cisplatin/Capecitabine EOX/EOF
• Cisplatin 80 mg/m2, day 1
• Capecitabine 1000 mg/m2 twice daily on day 1–14
Each cycle is repeated on day 22.
• Epirubicin 50 mg/m2, day 1
• Oxaliplatin 130 mg/m2, day 1
• Capecitabine 625 mg/m2 twice daily day 1–21 or 5-FU
200 mg/m2/day, continuously day 1–21
Each cycle is repeated on day 22
Cisplatin/S-1 FLOT
• Cisplatin 75 mg/m2, day 1
• S-1 25 mg/m2, twice daily day 1–21
Each cycle is repeated on day 29.
• Docetaxel 50 mg/m2, day 1
• Oxaliplatin 85 mg/m2, day 1
• Leucovorin 200 mg/mg2, day 1
• 5-FU 2600 mg/m2 (24-h infusion), day 1
Each cycle is repeated on day 15
Cisplatin/5-FU
• Cisplatin 75 (−100) mg/m2, day 1
• 5-FU 800 (−1000) mg/m2/day continuously day 1 to 5
or 1000 mg/m2/day cont. day 1–4
Each cycle is repeated on day 22
FLO
• Oxaliplatin 85 mg/m2, day 1
• Leucovorin 200 mg/m2, day 1
• 5-FU 2600 mg/m2 (24-h infusion), day 1
Each cycle is repeated on day 15
Mod. Folfox-6
• Oxaliplatin 85 mg/m2, day 1
• Leucovorin 400 mg/m2, day 1
• 5-FU 400 mg/m2 (bolus), day 1
• 5-FU 2400 mg/m2 (46-h infusion), day 1
Each cycle is repeated on day 15
Fig. 1 Study design
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Based on these assumptions and assuming exponential
distribution of survival times, 250 observed deaths are
required for confirmatory statistical analysis. Since the
power of the study is determined by the number of
deaths rather than the number of patients, there are a
range of sample sizes that could meet the objectives of
this trial. Assuming that 10 patients can be randomized
per month, with 297 patients (198 treated with S-1 and
99 treated with continued polychemotherapy), the total
study duration (accrual plus follow-up) will be about
39 months.
To account for the fact that merely roughly 75% of pa-
tients treated with primary chemotherapy will qualify for
randomization including patients who were enrolled in
the trial after completion of primary therapy, a total of
400 patients will be expected to be enrolled to the trial.
Overall survival (OS) will be defined as the time length
between randomization and the date of death from any
cause or the date of last follow-up in case of no docu-
mentation of death. Kaplan-Meier methods stratified by
treatment arm will be applied for estimating the prob-
ability of survival over time. For confirmatory analysis of
non-inferiority of S-1 a Cox proportional hazards regres-
sion model for overall survival with treatment as the only
factor and response to primary therapy and polyche-
motherapy as stratification variables will be fitted. Based
on the resulting adjusted hazard ratio for the treatment ef-
fect, significant non-inferiority will be claimed if the upper
limit of the associated one-sided 90% confidence limit
does not exceed the non-inferiority margin θ0.
Progression-free survival (PFS) will be defined as the
time length between the date of randomization and the
date of first disease progression or death (whichever occurs
first). Patients alive with no documented progression will
be censored at the last documented visit. For statistical
analysis, the distribution of progression-free survival time
will be described using Kaplan-Meier methods. To adjust
for stratification factors used at time of randomization,
Cox proportional hazards models will be applied.
When de-escalation with S-1 can be shown to be asso-
ciated with non-inferior overall survival, assessment
whether de-escalation improves QoL compared to
continuation of chemotherapy in maintenance phase
therapy is of special interest. Therefore, the following
statistical approach –exploratory in nature- is foreseen:
Quality of life will be evaluated using the validated
EORTC QLQ-C30 questionnaire and the gastric module
STO22.
Cumulative distribution of absolute changes (i.e. the
proportion of patients who experience every magnitude
of change in Global health status/QoL, functional and
symptom scales at a time point of interest compared to
baseline) will be presented. Furthermore, average scores
taken over the first 9 weeks of maintenance treatment
and taken over the whole maintenance phase will be
calculated for global health status/QoL and all other
functional and symptom scales of QoL-questionnaires.
Non-parametric (exact) Wilcoxon-Mann-Whitney tests
will be applied for treatment comparisons. To focus on
clinically relevant individual changes in QoL measures
only, responder analyses showing the rate of patients ex-
periencing a specific change that is meaningful to patients
are also pre-specified in the study protocol. To reduce
statistical multiplicity issues, a subset of QoL-parameters
of special interest is predefined in the study protocol.
Good clinical practice
This trial is accomplished in conformity with the princi-
pals of the Declaration of Helsinki and the Guidelines
for Good Clinical Practice in their current revision. The
trial will be carried out in keeping with national and
international legal and regulatory requirements.
Current study status
At the time of submitting this manuscript 104 patients
have been initially registered, 56 patients have been
randomized.
Discussion
The optimal duration of systemic polychemotherapy for
metastatic esophagogastric cancer is unknown. In many
clinical trials chemotherapy was given until tumour
progression or limiting toxicity, whereas in some other
trials treatment was stopped after a pre-defined period
of time.
No formal comparison of these two different strategies
has been performed.
Given the increasing toxicity rate with a prolonged
application of systemic polychemotherapy, the patients’
quality of life could be negatively affected.
During the past years maintenance and de-
escalation strategies have been examined in different
tumour types like colorectal or lung cancer. Mainten-
ance strategies led to acceptable therapy-related
toxicity on the one hand and prolonged the time-to-
tumour-progression and overall survival on the other
hand [20, 21]. So far and to the best of our know-
ledge, no published clinical trial has examined yet the
role of maintenance therapy in metastatic esophago-
gastric cancer.
Our study is designed to show non-inferiority of S-
1 maintenance therapy in comparison to continuation
of polychemotherapy. This comparison was chosen
instead of an observational arm without treatment
due to the fact that in clinical routine treatment of
metastatic esophagogastric cancer is often performed
until tumour progression or until limiting toxicity
occurs.
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In accordance to other clinical trials exploring a
platinum-based firstline therapy in metastatic gastric
cancer, patients with previous curative surgery with or
without perioperative systemic treatment are eligible, if
the primary therapy for metastatic disease starts at least
six months after the end of perioperative therapy,
whereas the subgroup of patients with an early relapse
(<6 months after the end of perioperative systemic treat-
ment) is excluded, anticipating a platinum-refractory dis-
ease in these patients.
Analysis of changes in the quality of life will be
performed during the primary period and maintenance
period to examine changes with the Qol in a de-
escalated therapeutic setting.
Translational analyses focus on the identification of a
subgroup of patients with a sustained benefit of S-1
based maintenance therapy.
This trial is conducted by the Young Medical Oncolo-
gists (YMO) Group in cooperation with the Gastric
Cancer Working Group of the Arbeitsgemeinschaft
Internistische Onkologie (AIO) within the German
Cancer Society (Sponsor: AIO-Studien-gGmbH).
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